IP Library Granted Patent US 9,907,859
Granted Patent B2
US 9,907,859 · App. 14/955,674 · Granted Mar 6, 2018

ST-246 liquid formulations and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,907,859
App. No.
14/955,674
Granted
Mar 6, 2018
Kind
B2
Abstract

The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.

Claims (14)

1. A method of treating orthopoxvirus infections and/or eczema vaccinatum comprising administering to a subject in need thereof a liquid pharmaceutical formulation comprising a therapeutically effective amount of ST-246 and hydroxypropyl-β-cyclodextrin and/or sulfobutyl-ether-β-cyclodextrin, and further comprising one or more pharmaceutically acceptable ingredients.

2. The method of claim 1 , wherein said liquid formulation is administered by parenteral administration.

3. The method of claim 1 , wherein said liquid formulation is administered by oral administration.

4. The method of claim 1 , wherein said liquid formulation is administered by topical administration.

5. The method of claim 1 , wherein said liquid formulation is administered by intravenous administration.

6. The method of claim 5 , wherein about 50 to about 500 mg of ST-246 is infused per single session of intravenous administration.

7. The method of claim 5 , wherein about 200 to about 400 mg of ST-246 is infused per single session of intravenous administration.

8. The method of claim 5 , wherein about 300 mg of ST-246 is infused per single session of intravenous administration.

9. The method of claim 5 , wherein said treatment is carried out for a period ranging from about 7 to about 30 days.

10. The method of claim 5 , wherein said treatment is carried out for a period ranging from about 7 to about 15 days.

11. The method of claim 5 , wherein the duration of each session of intravenous administration is from about 2 to about 24 hours.

12. The method of claim 5 , wherein said treatment is carried out continuously over the course of treatment at a dosage of about 50 to about 500 mg of ST-246 per day.

13. The method of claim 5 , wherein said intravenous administration is carried out during two sessions per day.

14. The method of claim 13 , wherein the duration of each session is from about 2 to about 12 hours.

Assignments (3)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 40349/0219 Recorded Mar 13, 2020
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: SIGA TECHNOLOGIES, INC.
Reel/Frame 052163/0014 →
SECURITY INTEREST Recorded Nov 16, 2016
From: SIGA TECHNOLOGIES, INC.
To: CORTLAND CAPITAL MARKET SERVICES, LLC
Reel/Frame 040349/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2015
From: TYAVANAGIMATT, SHANTHAKUMAR R.; ANDERSON, MELIALANI A.C.L.S.; WEIMERS, WILLIAM; KASI, GOPI KRISHNA; SAMUEL, N K PETER; BOLKEN, TOVE' C.; HRUBY, DENNIS E.
To: SIGA TECHNOLOGIES, INC.
Reel/Frame 037364/0460 →